News & Updates

Among fixed-dose combinations of inhaled corticosteroids/long-acting beta-2-adrenergic agonists (ICS/LABA), the newer combinations of fluticasone furoate/vilanterol (FF/VI) and fluticasone propionate/formoterol (FP/FORM) are associated with increased treatment persistence and lead to fewer exacerbations among patients with asthma, as shown in a study.

The eutectic-like mixture of prilocaine/lidocaine spray appears to work well in the treatment of men with various types of premature ejaculation, as reflected by a high treatment adherence, according to data from a real-world study.

Taking a statin after breast cancer surgery appears to reduce the risk of disease recurrence in Asians, especially among those with invasive cancers, as shown in a study from Singapore.

In the phase II/III EPIC-HR* trial, the novel oral antiviral nirmatrelvir-ritonavir reduced the risk of progression of COVID-19 to severe disease, as well as viral load, in symptomatic, high-risk, unvaccinated nonhospitalized adults confirmed to have SARS-CoV-2 infection.

Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.

Use of either empiric broad- or narrow-spectrum antibiotics in older patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) shows no remarkable difference in the primary outcome, reports a recent study.

A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.